Intermittent bolus dosing of ceftazidime in critically ill patients

Journal of Antimicrobial Chemotherapy

Volumn 40, Issue 2, 1997, Pages 269-273

  Young, Robert J ^a,c   Lipman, Jeffrey ^b   Gin, Tony ^a   Gomersall, Charles D ^a   Joynt, Gavin M ^a   Oh, Teik E ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^c ROYAL ADELAIDE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CEFTAZIDIME; CREATININE;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL INFECTION; BOLUS INJECTION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CREATININE BLOOD LEVEL; CRITICAL ILLNESS; DRUG BLOOD LEVEL; DRUG EFFICACY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; MINIMUM INHIBITORY CONCENTRATION; PSEUDOMONAS AERUGINOSA; TREATMENT FAILURE;

ADULT; AGED; CEFTAZIDIME; CEPHALOSPORINS; CRITICAL ILLNESS; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; PNEUMONIA;

EID: 0030802009     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/40.2.269     Document Type: Article

References (23)

1. Mouton, J. W. & den Hollander, J. G. (1994). Killing of Pseudomonas aeruginosa during continuous and intermittent infusion of ceftazidime in an in vitro pharmacokinetic model. Antimicrobial Agents and Chemotherapy 38, 931-6.
2. Vogelman, B. S. & Craig, W. A. (1985). Postantibiotic effects. Journal of Antimicrobial Chemotherapy 15, Suppl. A, 37-46.
3. Rudy, A. C. & Brater, D. C. (1994). Pharmacokinetics. In The Pharmacologic Approach to the Critically III Patient (Chernow, B., Ed.), pp. 3-17. Williams and Wilkins, Baltimore, MD.
4. van Dalen, R. & Vree, T. B. (1990). Pharmacokinetics of antibiotics in critically ill patients. Intensive Care Medicine 16, Suppl. 3, S235-8.
5. van Dalen, R., Vree, T. B., Baars, A. M. & Termond, E. (1986). Dosage adjustment for ceftazidime in patients with impaired renal function. European Journal of Clinical Pharmacology 30, 597-605.
6. van Dalen, R., Vree, T. B. & Baars, I. M. (1987). Influence of protein binding and severity of illness on renal elimination of four cephalosporin drugs in intensive care patients. Pharmaceutisch Weekblad Scientific Edition 9, 98-103.
7. Knaus, W. A. & Wagner, D. P. (1989). Multiple systems organ failure: epidemiology and prognosis. Critical Care Clinics 5, 221-32.
8. Ayrton, J. (1981). Assay of ceftazidime in biological fluids using high-pressure liquid chromatography. Journal of Antimicrobial Chemotherapy 8, Suppl. B, 227-31.
9. el Touny, M., el Guinaidy, M., Abd el Barry, M., Osman, L. & Sabbour, M. S. (1991). Pharmacokinetics of ceftazidime in patients with liver cirrhosis and ascites. Journal of Antimicrobial Chemotherapy 28, 95-100.
10. Harding, S. M., Monro, A. J., Thornton, J. E., Ayrton, J. & Hogg, M. I. J. (1981). The comparative pharmacokinetics of ceftazidime and cefotaxime in healthy volunteers. Journal of Antimicrobial Chemotherapy 6, Suppl. B, 263-72.
11. Mouton, J. W., Horrevorts, A. M., Mulder, P. G. H., Prens, E. P. & Michel, M. F. (1990). Pharmacokinetics of ceftazidime in serum and suction blister fluid during continuous and intermittent infusions in healthy volunteers. Antimicrobial Agents and Chemotherapy 34, 2307-11.
12. Sommers, D. K., Walters, L., Van Wyk, M., Harding, S. M., Paton, A. M. & Ayrton, J. (1983). Pharmacokinetics of ceftazidime in male and female volunteers. Antimicrobial Agents and Chemotherapy 23, 892-6.
13. Hoeprich, P. D. (1994). Antibacterial chemotherapy. In Infectious Diseases, 5th edn (Hoeprich, P. D., Jordan, M. C. & Ronald, A. R., Eds), pp. 247-74. Lippincott, Philadelphia, PA.
14. Dunn, M. & Wunderink, R. G. (1995). Ventilator-associated pneumonia caused by Pseudomonas infection. Clinics in Chest Medicine 16, 95-109.
15. Jones, R. N., Thornsberry, C. & Barry, A. L. (1984). In vitro evaluation of HR810, a new wide-spectrum aminothiazoly - methoxyimino cephalosporin. Antimicrobial Agents and Chemotherapy 25, 710-8.
16. Schentag, J. J., Smith, I. L., Swanson, D. J., DeAngelis, C., Fracasso, J. E., Vari, A. et al. (1984). Role for dual individualization with cefmenoxime. American Journal of Medicine 77, Suppl. 6A, 43-50.
17. Vogelman, B., Gudmundsson, S., Leggett, J., Turnidge, J., Ebert, S. & Craig, W. A. (1988). Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model. Journal of Infectious Diseases 158, 831-47.
18. Fantin, B., Farinotti, R., Thabaut, A. & Carbon, C. (1994). Conditions for the emergence of resistance to cefpirome and ceftazidime in experimental endocarditis due to Pseudomonas aeruginosa. Journal of Antimicrobial Chemotherapy 33, 563-9.
19. Nicolau, D. P., Quintiliani, R. & Nightingale, C. H. (1995). Antibiotic kinetics and dynamics for the clinician. Medical Clinics of North America 79, 477-95.
20. Verbist, L. & Verhaegen, J. (1981). Ceftazidime: comparative in-vitro study. Journal of Antimicrobial Chemotherapy 8, Suppl. B, 67-71.
21. Scribner, R. K., Marks, M. I., Weber, A. H., Tarpay, M. M. & Welch, D. F. (1982). Activities of various β-lactams and aminoglycosides, alone and in combination, against isolates of Pseudomonas aeruginosa from patients with cystic fibrosis. Antimicrobial Agents and Chemotherapy 21, 939-43.
22. Cunha, B. A. & Ortega, A. M. (1995). Antibiotic failure. Medical Clinics of North America 79, 663-72.
23. Benet, L. Z. & Williams, R. L. (1990). Design and optimization of dosage regimens: pharmacokinetic data. In Goodman and Gillman's The Pharmacological Basis of Therapeutics, 8th edn (Gilman, A. G., Rall, T. W., Nies, A. S. & Taylor, P., Eds), pp. 1650-735. McGraw-Hill, New York, NY.